At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MDGL Madrigal Pharmaceuticals
Trading 08-05 11:30:31 EDT
505.50
-2.06
-0.41%
High516.23Low503.65Vol83.50K
Open510.88D1 Closing507.56Amplitude2.48%
Mkt Cap11.65BTradable Cap7.00BTotal Shares23.06M
T/O42.49MT/O Rate0.60%Tradable Shares13.85M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Arrowhead Pharmaceuticals Q3 Revenue Jumps on Redemplo Growth
Reuters  ·  04:10
Arrowhead Pharmaceuticals Q3 Revenue Jumps on Redemplo Growth
Madrigal upgraded to Outperform from Peer Perform at Wolfe Research
TIPRANKS  ·  08-04 17:25
Madrigal upgraded to Outperform from Peer Perform at Wolfe Research
Madrigal Pharmaceuticals is Maintained at Overweight by Barclays
Dow Jones  ·  08-03 20:14
Madrigal Pharmaceuticals is Maintained at Overweight by Barclays
Madrigal Pharmaceuticals price target lowered to $962 from $964 at Barclays
TIPRANKS  ·  08-03 17:45
Madrigal Pharmaceuticals price target lowered to $962 from $964 at Barclays
Movement Alert｜Madrigal Pharmaceuticals Falls 5.07% in Regular Trading, Q2 Earnings Loss Widening Extends Selling Pressure
Market Focus  ·  07-31
Movement Alert｜Madrigal Pharmaceuticals Falls 5.07% in Regular Trading, Q2 Earnings Loss Widening Extends Selling Pressure
Madrigal Pharmaceuticals Inc : Bofa Global Research Cuts Price Objective to $543 from $553
THOMSON REUTERS  ·  07-31
Madrigal Pharmaceuticals Inc : Bofa Global Research Cuts Price Objective to $543 from $553
Neurocrine Biosciences Q2 Adjusted EPS Beats Expectations, Revenue Rises on Product Portfolio Growth
Reuters  ·  07-31
Neurocrine Biosciences Q2 Adjusted EPS Beats Expectations, Revenue Rises on Product Portfolio Growth
Madrigal Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  07-31
Madrigal Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Movement Alert｜Madrigal Pharmaceuticals Falls 12.78% in Regular Trading, Q2 Revenue Beats Expectations but Year-over-Year Loss Widens
Market Focus  ·  07-30
Movement Alert｜Madrigal Pharmaceuticals Falls 12.78% in Regular Trading, Q2 Revenue Beats Expectations but Year-over-Year Loss Widens
Stock Track | Madrigal Pharmaceuticals Plummets 7.56% in Pre-market as Q2 Loss Widens and Expenses Surge Despite Revenue Beat
Stock Track  ·  07-30
Stock Track | Madrigal Pharmaceuticals Plummets 7.56% in Pre-market as Q2 Loss Widens and Expenses Surge Despite Revenue Beat
Movement Alert｜Madrigal Pharmaceuticals Falls 6.74% in Pre-Market Trading, Q2 Earnings Beat Estimates but Per-Share Loss Widens Year-Over-Year
Market Focus  ·  07-30
Movement Alert｜Madrigal Pharmaceuticals Falls 6.74% in Pre-Market Trading, Q2 Earnings Beat Estimates but Per-Share Loss Widens Year-Over-Year
Alnylam Q2 Revenue Rises 67% on Increased Demand for Amvuttra
Reuters  ·  07-30
Alnylam Q2 Revenue Rises 67% on Increased Demand for Amvuttra
Stock Track | Madrigal Pharmaceuticals Plunges 6.14% in Pre-market as Q2 Loss Widens and Expenses Surge Despite Revenue Growth
Stock Track  ·  07-30
Stock Track | Madrigal Pharmaceuticals Plunges 6.14% in Pre-market as Q2 Loss Widens and Expenses Surge Despite Revenue Growth
Madrigal Q2 FY26 Net Loss Widens to $57.9 Million; Net Sales Rise 71% to $364.3 Million
Reuters  ·  07-30
Madrigal Q2 FY26 Net Loss Widens to $57.9 Million; Net Sales Rise 71% to $364.3 Million
Madrigal Pharmaceuticals Q2 Product Revenue USD 364.252 Million
Reuters  ·  07-30
Madrigal Pharmaceuticals Q2 Product Revenue USD 364.252 Million
Madrigal Pharmaceuticals Q2 Revenue Rises 71% on Rezdiffra Demand
Reuters  ·  07-30
Madrigal Pharmaceuticals Q2 Revenue Rises 71% on Rezdiffra Demand
Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q2 Net Loss $1.99 a Share, vs. FactSet Est of $2.68 Loss
MT Newswires Live  ·  07-30
Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q2 Net Loss $1.99 a Share, vs. FactSet Est of $2.68 Loss
Madrigal Pharmaceuticals Q2 EPS $(1.99) Beats $(2.50) Estimate, Sales $364.252M Beat $353.178M Estimate
Benzinga Earnings  ·  07-30
Madrigal Pharmaceuticals Q2 EPS $(1.99) Beats $(2.50) Estimate, Sales $364.252M Beat $353.178M Estimate
Madrigal Pharmaceuticals Q2 EPS USD -1.99
THOMSON REUTERS  ·  07-30
Madrigal Pharmaceuticals Q2 EPS USD -1.99
Madrigal Pharmaceuticals Q2 Operating Income USD -56.308 Million
THOMSON REUTERS  ·  07-30
Madrigal Pharmaceuticals Q2 Operating Income USD -56.308 Million

Introduction

Company Name.
Madrigal Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.
Issue price:
--